XML 143 R99.htm IDEA: XBRL DOCUMENT v3.22.4
Principal changes in the scope of consolidation in 2021 and 2020 - Additional Information (Details)
€ / shares in Units, $ / shares in Units, € in Millions, $ in Millions
 12 Months Ended
Dec. 03, 2021
EUR (€)
Nov. 09, 2021
EUR (€)
Apr. 29, 2021
EUR (€)
Apr. 16, 2021
May 29, 2020
EUR (€)
shares
May 29, 2020
USD ($)
shares
Feb. 14, 2020
EUR (€)
Dec. 31, 2022
EUR (€)
shares
Dec. 31, 2021
EUR (€)
shares
Dec. 31, 2020
EUR (€)
shares
Nov. 09, 2021
USD ($)
$ / shares
Sep. 14, 2021
EUR (€)
Sep. 14, 2021
$ / shares
Aug. 03, 2021
$ / shares
Apr. 09, 2021
EUR (€)
Apr. 09, 2021
USD ($)
Apr. 08, 2021
EUR (€)
Apr. 08, 2021
USD ($)
Nov. 02, 2020
€ / shares
shares
Sep. 28, 2020
EUR (€)
Sep. 28, 2020
$ / shares
Jun. 23, 2020
May 29, 2020
$ / shares
Jan. 23, 2020
EUR (€)
Jan. 23, 2020
$ / shares
Disclosure of detailed information about business combination [line items]                                                  
Net cash flow on acquisition [1]               € 992 € 5,594 € 5,336 [2]                              
Percentage of share capital owned (in percent)               1                                  
Investments accounted for using the equity method               € 677 250 201 [3]                              
Gain on Regeneron investment arising from transaction of May 29, 2020               0 0 7,382 [4]                              
Net proceeds from sale of Regeneron shares on May 29, 2020               0 0 10,370 [2]                              
Gains on disposal of non-current assets, net of tax             € 129                                    
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax             € 311 € 1,488 [5] € 676 [5] € 918 [2],[5]                              
Translate Bio                                                  
Disclosure of detailed information about business combination [line items]                                                  
Investments in equity instruments designated at fair value through OCI, ownership percentage                 8.00%     5.00%                          
Regeneron                                                  
Disclosure of detailed information about business combination [line items]                                                  
Non-current financial assets, number of shares (in shares) | shares         400,000       279,766                                
Proceeds from sales of investments accounted for using equity method, before transaction costs         € 10,575                                        
Investments accounted for using the equity method         3,668                                        
Gain on Regeneron investment arising from transaction of May 29, 2020         7,382                                        
Transaction-related costs         64                                        
Gains (losses) on remeasuring available-for-sale financial assets, net of tax         157                                        
Quoted stock market price per share (in USD per share) | $ / shares                                             $ 612.81    
Fair value through other comprehensive income         221                                        
Tax expense on disposal of investment         502                                        
Net proceeds from sale of Regeneron shares on May 29, 2020         10,370                                        
Regeneron | Reserve of exchange differences on translation                                                  
Disclosure of detailed information about business combination [line items]                                                  
Gain on Regeneron investment arising from transaction of May 29, 2020         € 318                                        
Regeneron | 2018 Letter Agreement                                                  
Disclosure of detailed information about business combination [line items]                                                  
Aggregate number of Regeneron shares that could be sold for cemiplimab and dupilimab funding costs (in shares) | shares                   1,400,000                              
Sale of stock, number of shares issued in transaction, shares agreement (in shares) | shares               779,320                                  
Regeneron | Public offering                                                  
Disclosure of detailed information about business combination [line items]                                                  
Sale of stock, number of shares issued in transaction (in shares) | shares         13,000,000 13,000,000                                      
Sale of stock, price per share (in USD per share) | $ / shares                                             515    
Proceeds from sales of investments accounted for using equity method, before transaction costs | $           $ 6,703                                      
Regeneron | Public offering | Sanofi SA                                                  
Disclosure of detailed information about business combination [line items]                                                  
Sale of stock, number of shares issued in transaction (in shares) | shares         10,600,000 10,600,000                                      
Regeneron | Repurchase from the counterpart | Regeneron Pharmaceuticals, INC                                                  
Disclosure of detailed information about business combination [line items]                                                  
Sale of stock, price per share (in USD per share) | $ / shares                                             $ 509.85    
Proceeds from sales of investments accounted for using equity method, before transaction costs | $           $ 5,000                                      
Shares agreement, sale of stock, number of shares issued in transaction (in shares) | shares         9,800,000                                        
Kymab                                                  
Disclosure of detailed information about business combination [line items]                                                  
Cash transferred                             € 136 $ 160 € 973 $ 1,100              
Commitments related to milestone payments for projects under collaboration agreements | $                                   $ 350              
Other intangible assets                                 € 965                
Net cash flow on acquisition                 € 932                                
Kiadis                                                  
Disclosure of detailed information about business combination [line items]                                                  
Other intangible assets     € 339                                            
Net cash flow on acquisition                 326                                
Number of shares included in public offer (in shares) | shares                                     61,000,000            
Purchase price (in EUR/USD per share) | € / shares                                     € 5.45            
Proportion of issued and outstanding share capital tendered into the public offer       95.03%                                          
Financial interest in principal fully consolidated companies     97.39%                                            
Tidal Therapeutics                                                  
Disclosure of detailed information about business combination [line items]                                                  
Commitments related to milestone payments for projects under collaboration agreements | $                               $ 310                  
Other intangible assets                             € 130                    
Net cash flow on acquisition                 135                                
Translate Bio                                                  
Disclosure of detailed information about business combination [line items]                                                  
Other intangible assets                       € 396                          
Net cash flow on acquisition                 € 2,333                                
Purchase price (in EUR/USD per share) | $ / shares                         $ 0.38 $ 0.38                      
Goodwill                       € 2,118                          
Investments in equity instruments designated at fair value through OCI, ownership percentage                                           5.00%      
Kadmon                                                  
Disclosure of detailed information about business combination [line items]                                                  
Other intangible assets   € 1,739                                              
Net cash flow on acquisition   € (1,575)                                              
Purchase price (in EUR/USD per share) | $ / shares                     $ 9.50                            
Estimated purchase price on a fully-diluted basis | $                     $ 1,900                            
Origimm Biotechnology GmbH                                                  
Disclosure of detailed information about business combination [line items]                                                  
Cash transferred € 55                                                
Commitments related to milestone payments for projects under collaboration agreements 95                                                
Other intangible assets 55                                                
Net cash flow on acquisition € (50)                                                
Principia                                                  
Disclosure of detailed information about business combination [line items]                                                  
Other intangible assets                                       € 2,534          
Purchase price (in EUR/USD per share) | $ / shares                                         $ 100        
Goodwill                                       € 912          
Synthorx                                                  
Disclosure of detailed information about business combination [line items]                                                  
Other intangible assets                                               € 1,549  
Purchase price (in EUR/USD per share) | $ / shares                                                 $ 68
Goodwill                                               € 930  
[1] (f)    This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For 2022, it includes the net cash outflow on the acquisition of Amunix (see Note D.1.). For 2021, it includes the net cash outflows on the acquisitions of Kymab, Kiadis, Tidal, Translate Bio, Kadmon and Origimm (see Note D.2.1.). For 2020, it includes the net cash outflows on the acquisitions of Synthorx and Principia (see Note D.2.2.).
[2] (j)    Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[3] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[4] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[5] (g)    For 2022, 2021 and 2020, this line item mainly comprises disposals of assets and activities related to portfolio streamlining and disposals of equity and debt instruments. For 2020, it also includes the sale to Baxter of operations relating to Seprafilm® for a selling price (before taxes) of €311 million. (see Note D.7.1.).